查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405963

小分子CDMO市場規模、佔有率和趨勢分析報告：按產品、藥物類型、應用、地區和細分市場預測，2024-2030年

Small Molecule CDMO Market Size, Share & Trends Analysis Report By Drug Type (Generics, Innovators), By Product (APIs, Finished Drug Products), By Application (Oncology, CVD, CNS Conditions), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

小分子 CDMO 市場成長與趨勢：

Grand View Research, Inc.的最新研究顯示，預計2030年全球小分子CDMO市場規模將達到1,084.6億美元，2024年至2030年複合年成長率為7.1%。

開發小分子藥物開發創新技術，以小分子治療藥物為重點拓展藥物管線，並依托CDMO（合約藥物開發和受託製造廠商）提供具有成本效益的專業製造服務。需求不斷成長，法律規範支持高效藥物開發和製造流程以及 CDMO 擴大製造能力以滿足行業需求是支持市場成長的一些因素。創新和輕鬆進入診所是製藥公司的重要因素。

小型企業和專業製藥公司越來越依賴滿足行業內的這些關鍵要求。許多 CDMO 將自己定位為一站式服務公司。一站式服務模式意味著 CDMO 提供從原料藥(API) 到劑型、從早期開發到商業化的一切服務。為了提供此類服務，CDMO 必須擁有廣泛的實行技術和專門的處理能力來解決特定的問題說明。全球範圍內大量提供全面研究、開發和製造服務的 CDMO 預計將支持市場成長。慢性病的高盛行率也是支持新型小分子療法開發的主要因素，推動了對 CDMO 服務的需求。

國際糖尿病聯盟（IDF）表示，該國糖尿病盛行率正在逐漸上升。報告稱，2022年中國將有超過1.4億人被診斷為糖尿病，2030年將有1.744億人被診斷為糖尿病。攝取大量不健康脂肪和久坐的生活方式是導致糖尿病發生率增加的主要因素。糖尿病負擔的增加預計將推動該國對 CDMO 服務的需求。對藥品研發的大量投資是產業成長的關鍵驅動力。隨著製藥公司專注於發現和開發小分子療法，對 CDMO 服務的需求也在增加。這些服務對於小分子藥物的高效且經濟高效的開發和製造至關重要。

小分子 CDMO 市場報告亮點

  • 由於開發新藥的舉措措施增加，原料藥細分市場在 2023 年佔最大佔有率，達到 62.3%。大型製藥企業強大的藥品管道也支持該行業的成長。
  • 預計 2024 年至 2030 年，學名藥領域的複合年成長率將達到 8.0%，是最高的。癌症、糖尿病和心血管疾病（CVD）等疾病的沉重負擔以及政府為改善學名藥的獲取而做出的努力是促進該行業成長的主要因素。
  • 由於全球癌症患者數量的增加，2023年腫瘤領域的銷售額佔有率最高，達35.1%。此外，更強力的政府報銷政策和對小分子癌症藥物開發的資金籌措增加預計將支持該行業的成長。
  • 預計 2024 年至 2030 年，亞太地區複合年成長率最高，為 7.7%。亞太地區，尤其是中國和印度，由於製造成本顯著低於北美和歐洲且法律更完善，仍然是主導的區域市場。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章小分子 CDMO 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 小分子CDMO市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章小分子CDMO市場：產品預估及趨勢分析

  • 定義和範圍
  • 2023年及2030年產品市場佔有率
  • 細分儀表板
  • 按產品分類的全球小分子 CDMO 市場展望
  • 2018年至2030年市場規模、預測與趨勢分析
    • 活性藥物成分 (API)
    • 醫藥成品

第5章 小分子CDMO市場：藥物類型預估及趨勢分析

  • 定義和範圍
  • 2023 年和 2030 年藥物類型市場佔有率
  • 細分儀表板
  • 按藥物類型分類的全球小分子 CDMO 市場展望
  • 2018年至2030年市場規模、預測與趨勢分析
    • 創新者
    • 非專利的

第6章 小分子CDMO市場：應用預估與趨勢分析

  • 定義和範圍
  • 2023年及2030年應用市場佔有率
  • 細分儀表板
  • 全球小分子CDMO市場按應用前景展望
  • 2018年至2030年市場規模、預測與趨勢分析
    • 瘤
    • 循環系統疾病
    • 中樞神經系統 (CNS) 疾病
    • 自體免疫/發炎
    • 其他

第7章小分子CDMO市場：區域估計與趨勢分析

  • 2023 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 印度
    • 中國
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭形勢

  • 市場參與企業分類
    • 創新者
    • 市場領導者
    • 新興玩家
    • 2023 年公司市場佔有率分析
  • 公司簡介
    • Lonza
    • Catalent, Inc
    • Thermo Fisher Scientific Inc.
    • Cambrex Corporation
    • Bellen Chemistry
    • Siegfried Holding AG
    • Recipharm AB
    • Eurofins Scientific
    • Aurigene Pharmaceutical Services Ltd.
    • CordenPharma International
Product Code: GVR-4-68040-165-6

Small Molecule CDMO Market Growth & Trends:

The global small molecule CDMO market size is expected to reach USD 108.46 billion by 2030, registering a CAGR of 7.1% from 2024 to 2030, according to a new study by Grand View Research, Inc. Exploration of innovative technologies in small molecule drug development, expansion of pharmaceutical pipelines with a focus on small molecule therapeutics, growing reliance on contract development and manufacturing organizations (CDMOs) for cost-effective and specialized manufacturing services, regulatory frameworks supporting efficient drug development & manufacturing processes, and CDMOs expanding manufacturing capacities to meet industry demands are few of the factors supporting market growth. For pharmaceutical companies, innovation and easy access to clinics are critical factors.

Small-scale companies and specialty pharmaceutical players increasingly rely on delivering these important requirements within the industry. Many CDMOs establish themselves as one-stop-shop companies. The one-stop-shop service model is where a CDMO offers everything, from active pharmaceutical ingredient (API) to dosage form and early development to commercialization. To provide these services, a CDMO must have a wide range of enabling technologies and specialized handling capabilities that help address specific problem statements. A significant number of CDMOs across the globe providing all research, development, and manufacturing services is expected to support market growth. The high prevalence of chronic ailments is another considerable factor supporting the development of novel small molecule-based therapeutics, thus boosting CDMO services demand.

The International Diabetes Federation (IDF) states that the incidence of diabetes is rising gradually in the country. It states that in 2022, over 140 million people in China had diabetes, and 174.4 million are expected to be diagnosed by 2030. High consumption of unhealthy fats and a sedentary lifestyle are major factors contributing to the high incidence of diabetes. The growing burden of diabetes is expected to drive CDMO services demand in the country. Substantial investment in pharmaceutical R&D is a significant driver bolstering industry growth. As pharmaceutical companies intensify their efforts in discovering & developing small molecule therapeutics, there is a corresponding rise in demand for CDMO services. These services are crucial in the efficient & cost-effective development & manufacturing of small-molecule drugs.

Small Molecule CDMO Market Report Highlights:

  • The API segment accounted for the largest share of 62.3% in 2023 due to increased R&D initiatives for novel medicine development. The robust drug pipelines of major pharmaceutical players also propel segment growth
  • The generics drug type segment is anticipated to have the highest CAGR of 8.0% from 2024 to 2030. The high burden of diseases, such as cancer, diabetes, and cardiovascular disorders (CVDs), and initiatives by the governments to improve access to generic drugs are the key factors contributing to segment growth
  • The oncology segment held the highest revenue share of 35.1% in 2023 owing to an increasing number of cancer cases globally. Furthermore, increased government reimbursement policies and a rise in financing for developing small molecule oncology therapies are expected to boost segment growth
  • Asia Pacific is anticipated to witness the highest CAGR of 7.7% from 2024 to 2030. Due to significantly cheaper manufacturing costs than North America & Europe and favorable laws, Asia Pacific, particularly China & India, has remained the dominant regional market

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Drug Type
    • 1.1.3. Application
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
      • 1.3.5.1. Data for primary interviews in North America
      • 1.3.5.2. Data for primary interviews in Europe
      • 1.3.5.3. Data for primary interviews in Asia Pacific
      • 1.3.5.4. Data for primary interviews in Latin America
      • 1.3.5.5. Data for Primary interviews in MEA
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Parent Market Analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Drug Type outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Small Molecule CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rise in drug development pipelines
      • 3.2.1.2. Growing reliance on CDMOS for cost-effective and specialized manufacturing services.
      • 3.2.1.3. Capacity expansions by CDMOS
      • 3.2.1.4. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Growing demand for biologics
      • 3.2.2.2. Complexity and challenges in synthesis of certain small molecules, impacting manufacturing efficiency
  • 3.3. Small Molecule CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Small Molecule CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. Active Pharmaceutical Ingredients (API)
    • 4.1.2. Finished Drug Products
  • 4.2. Product Market Share, 2023 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Global Small Molecule CDMO Market by Product Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.5.1. Active Pharmaceutical Ingredients (APIs)
      • 4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.2. Finished Drug Products
      • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Small Molecule CDMO Market: Drug Type Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Innovators
    • 5.1.2. Generics
  • 5.2. Drug Type Market Share, 2023 & 2030
  • 5.3. Segment Dashboard
  • 5.4. Global Small Molecule CDMO Market by Drug Type Outlook
  • 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.5.1. Innovators
      • 5.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.5.2. Generics
      • 5.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Small Molecule CDMO Market: Application Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Oncology
    • 6.1.2. Cardiovascular Disease
    • 6.1.3. Central Nervous System (CNS) Conditions
    • 6.1.4. Autoimmune/Inflammation
    • 6.1.5. Others
  • 6.2. Application Market Share, 2023 & 2030
  • 6.3. Segment Dashboard
  • 6.4. Global Small Molecule CDMO Market by Application Outlook
  • 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.5.1. Oncology
      • 6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.2. Cardiovascular Disease
      • 6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.3. Central Nervous System (CNS) Conditions
      • 6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.4. Autoimmune/Inflammation
      • 6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.5.5. Others
      • 6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Small Molecule CDMO Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. North America
    • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key Country Dynamics
      • 7.5.1.2. Competitive Scenario
      • 7.5.1.3. Regulatory Framework
      • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 7.5.2. Germany
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 7.5.3. France
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 7.5.4. Italy
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 7.5.5. Spain
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 7.5.6. Denmark
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 7.5.7. Sweden
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 7.5.8. Norway
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key Country Dynamics
      • 7.6.1.2. Competitive Scenario
      • 7.6.1.3. Regulatory Framework
      • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 7.6.2. India
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 7.6.4. South Korea
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 7.6.6. Thailand
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key Country Dynamics
      • 7.7.1.2. Competitive Scenario
      • 7.7.1.3. Regulatory Framework
      • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 7.7.2. Mexico
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key Country Dynamics
      • 7.8.1.2. Competitive Scenario
      • 7.8.1.3. Regulatory Framework
      • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 7.8.4. Kuwait
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
    • 8.1.1. Innovators
    • 8.1.2. Market Leaders
    • 8.1.3. Emerging Players
    • 8.1.4. Company Market Share Analysis, 2023
  • 8.2. Company Profiles
    • 8.2.1. Lonza
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Service benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Catalent, Inc
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Service benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Thermo Fisher Scientific Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Service benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Cambrex Corporation
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Service benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Bellen Chemistry
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Service benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Siegfried Holding AG
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Service benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Recipharm AB
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Service benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Eurofins Scientific
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Service benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Aurigene Pharmaceutical Services Ltd.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Service benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. CordenPharma International
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Service benchmarking
      • 8.2.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 North America Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 4 North America Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 5 North America Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 7 U.S. Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 10 Canada Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 14 Europe Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 15 Europe Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 16 Germany Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 17 Germany Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 18 Germany Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 19 UK Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 20 UK Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 21 UK Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 22 France Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 23 France Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 24 France Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 25 Italy Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 26 Italy Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 27 Italy Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 28 Spain Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 29 Spain Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 30 Spain Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 31 Denmark Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 32 Denmark Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 33 Denmark Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 34 Sweden Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 35 Sweden Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 36 Sweden Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 37 Norway Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 38 Norway Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 39 Norway Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 44 China Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 45 China Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 46 China Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 47 Japan Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 48 Japan Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 50 India Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 51 India Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 52 India Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 53 South Korea Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 54 South Korea Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 55 South Korea Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 56 Australia Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 57 Australia Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 58 Australia Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 59 Thailand Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Thailand Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 61 Thailand Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 62 Latin America Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 63 Latin America Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 64 Latin America Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 65 Brazil Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Brazil Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 67 Brazil Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 68 Mexico Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 69 Mexico Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 70 Mexico Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 71 Argentina Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 72 Argentina Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 73 Argentina Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 74 MEA Small Molecule CDMO market, by region, 2018 - 2030 (USD Million)
  • Table 75 MEA Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 76 MEA Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 77 MEA Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 78 South Africa Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 79 South Africa Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 80 South Africa Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 84 UAE Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 85 UAE Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 86 UAE Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)
  • Table 87 Kuwait Small Molecule CDMO market, by Product, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Small Molecule CDMO market, by Drug Type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Small Molecule CDMO market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 QFD modeling for market share assessment
  • Fig. 11 Market formulation & validation
  • Fig. 12 Small Molecule CDMO market: market outlook
  • Fig. 13 Small Molecule CDMO competitive insights
  • Fig. 14 Parent market outlook
  • Fig. 15 Related/ancillary market outlook
  • Fig. 16 Industry value chain analysis
  • Fig. 17 Small Molecule CDMO market driver impact
  • Fig. 18 Small Molecule CDMO market restraint impact
  • Fig. 19 Small Molecule CDMO market: Product movement analysis
  • Fig. 20 Small Molecule CDMO market: Product outlook and key takeaways
  • Fig. 21 Active Pharmaceutical Ingredients (API) market estimates and forecast, 2018 - 2030
  • Fig. 22 Finished Drug Products estimates and forecast, 2018 - 2030
  • Fig. 23 Small Molecule CDMO Market: Drug Type Movement Analysis
  • Fig. 24 Small Molecule CDMO market: Drug Type outlook and key takeaways
  • Fig. 25 Innovators market estimates and forecast, 2018 - 2030
  • Fig. 26 Generics market estimates and forecast, 2018 - 2030
  • Fig. 27 Small Molecule CDMO market: application movement analysis
  • Fig. 28 Small Molecule CDMO market: application outlook and key takeaways
  • Fig. 29 Oncology market estimates and forecast, 2018 - 2030
  • Fig. 30 Cardiovascular Disease market estimates and forecast, 2018 - 2030
  • Fig. 31 Central Nervous System (CNS) Conditions market estimates and forecast, 2018 - 2030
  • Fig. 32 Autoimmune/Inflammation market estimates and forecast, 2018 - 2030
  • Fig. 33 Other market estimates and forecast, 2018 - 2030
  • Fig. 34 Global Small Molecule CDMO market: Regional movement analysis
  • Fig. 35 Global Small Molecule CDMO market: Regional outlook and key takeaways
  • Fig. 36 North America
  • Fig. 37 North America market estimates and forecast, 2018 - 2030
  • Fig. 38 U.S.
  • Fig. 39 U.S. market estimates and forecast, 2018 - 2030
  • Fig. 40 Canada
  • Fig. 41 Canada market estimates and forecast, 2018 - 2030
  • Fig. 42 Europe
  • Fig. 43 Europe market estimates and forecast, 2018 - 2030
  • Fig. 44 UK
  • Fig. 45 UK market estimates and forecast, 2018 - 2030
  • Fig. 46 Germany
  • Fig. 47 Germany market estimates and forecast, 2018 - 2030
  • Fig. 48 France
  • Fig. 49 France market estimates and forecast, 2018 - 2030
  • Fig. 50 Italy
  • Fig. 51 Italy market estimates and forecast, 2018 - 2030
  • Fig. 52 Spain
  • Fig. 53 Spain market estimates and forecast, 2018 - 2030
  • Fig. 54 Denmark
  • Fig. 55 Denmark market estimates and forecast, 2018 - 2030
  • Fig. 56 Sweden
  • Fig. 57 Sweden market estimates and forecast, 2018 - 2030
  • Fig. 58 Norway
  • Fig. 59 Norway market estimates and forecast, 2018 - 2030
  • Fig. 60 Asia Pacific
  • Fig. 61 Asia Pacific market estimates and forecast, 2018 - 2030
  • Fig. 62 China
  • Fig. 63 China market estimates and forecast, 2018 - 2030
  • Fig. 64 Japan
  • Fig. 65 Japan market estimates and forecast, 2018 - 2030
  • Fig. 66 India
  • Fig. 67 India market estimates and forecast, 2018 - 2030
  • Fig. 68 Thailand
  • Fig. 69 Thailand market estimates and forecast, 2018 - 2030
  • Fig. 70 South Korea
  • Fig. 71 South Korea market estimates and forecast, 2018 - 2030
  • Fig. 72 Australia
  • Fig. 73 Australia market estimates and forecast, 2018 - 2030
  • Fig. 74 Latin America
  • Fig. 75 Latin America market estimates and forecast, 2018 - 2030
  • Fig. 76 Brazil
  • Fig. 77 Brazil market estimates and forecast, 2018 - 2030
  • Fig. 78 Mexico
  • Fig. 79 Mexico market estimates and forecast, 2018 - 2030
  • Fig. 80 Argentina
  • Fig. 81 Argentina market estimates and forecast, 2018 - 2030
  • Fig. 82 Middle East and Africa
  • Fig. 83 Middle East and Africa market estimates and forecast, 2018 - 2030
  • Fig. 84 South Africa
  • Fig. 85 South Africa market estimates and forecast, 2018 - 2030
  • Fig. 86 Saudi Arabia
  • Fig. 87 Saudi Arabia market estimates and forecast, 2018 - 2030
  • Fig. 88 UAE
  • Fig. 89 UAE market estimates and forecast, 2018 - 2030
  • Fig. 90 Kuwait
  • Fig. 91 Kuwait market estimates and forecast, 2018 - 2030
  • Fig. 92 Market share of key market players - Small Molecule CDMO market